亚洲Stargardt病患者视网膜下移植胚胎干细胞来源视网膜色素上皮细胞的3年安全性评估
这项前瞻性非随机I期临床试验纳入3例Stargardt黄斑营养不良患者,患眼最佳矫正视力不优于20/400,行经平坦部玻璃体切除后以半自动视网膜下注射法移植人胚胎干细胞来源视网膜色素上皮细胞。3年随访期间未发生严重不良事件,功能与解剖结果优于ProgStar研究报告的自然病程,1例最佳矫正视力改善、其余稳定,提示长期安全性、耐受性和可行性。
要点
- 3例Stargardt病患者视网膜下移植hESC-RPE细胞后3年内未发生严重不良事件。
- 功能与解剖结果优于ProgStar研究报告的自然病程,1例最佳矫正视力改善,其余稳定。
- 提示hESC-RPE细胞视网膜下移植在再生医学中具有长期安全性、耐受性和可行性。
核心结论
- 视网膜下移植人胚胎干细胞来源视网膜色素上皮细胞在亚洲Stargardt病患者中显示长期安全性、耐受性和可行性。
研究设计与样本
- 前瞻性非随机I期临床试验纳入3例Stargardt黄斑营养不良患者,均接受视网膜下hESC-RPE细胞移植。
主要发现
- 移植后3年随访期间未发生严重不良事件。
- 功能和解剖结果与ProgStar研究报告的自然病程相比表现有利。
- 1例患者最佳矫正视力改善,其余患者在3年随访期内最佳矫正视力稳定。
关键数值与推荐
- 所有移植受者 central visual acuity 不优于20/400。
- 对视力较差眼行经平坦部玻璃体切除,RPE细胞在平衡盐溶液plus中重悬后以半自动视网膜下注射法注入视网膜下腔。
临床怎么用
- 该I期试验结果为hESC-RPE细胞视网膜下移植治疗Stargardt病提供了初步的长期安全性和耐受性证据。
局限性
- 样本量仅3例,为非随机设计,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although human embryonic stem cells (hESCs) have been considered a potential therapeutic option for regenerative medicine, there are some concerns regarding tumorigenicity, immunogenicity and ethical considerations. Stargardt macular dystrophy (SMD) is the most common form of juvenile macular degeneration that causes early onset blindness. Therapeutic options for SMD remain limited, although several treatment strategies are currently under investigation. Here, we report a 3-year assessment of a phase I clinical trial involving subretinal transplantation of hESC-retinal pigment epithelium (RPE) cells in patients with SMD. METHODS: This prospective, non-randomised clinical trial included three patients with SMD. All transplant recipients had central visual acuity no better than 20/400. Trans-pars plana vitrectomy was performed in the eye with poorer vision. RPE cells were reconstituted in balanced salt solution plus, then injected into the subretinal space using a semi-automated subretinal injection method. RESULTS: No serious adverse events occurred throughout the 3-year period following the injection of hESC-RPE cells. The functional and anatomical results were favourable, compared with the natural course of SMD reported in the ProgStar study. One patient showed best-corrected visual acuity improvement, while the other patients had stable best-corrected visual acuity during the 3-year follow-up period. CONCLUSION: These results suggest the long-term safety, tolerability, and feasibility of subretinal hESC-derived RPE cell transplantation in regenerative medicine. TRIAL REGISTRATION NUMBER: NCT01625559.
引用
- Sung Y, Lee MJ, Choi J, et al. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol. 2020. PMID: 32727729. doi:10.1136/bjophthalmol-2020-316225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。